Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG vaccine for prevention of COPD exacerbations
ISRCTN62785249Phase 4Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bcg vaccine in chronic obstructive pulmonary disease (COPD), sponsored by University of Birmingham. Primary endpoint: Rate of moderate to severe acute exacerbations of chronic obstructive pulmonary disease. Started Oct 2025; status: recruiting.
02
Drugs
bcg vaccine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ISRCTN62785249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN62785249.